In partnership with
Bullish Trend: PepsiCo Expands with Siete Foods; Busey Gains Federal Approval for CrossFirst Merger; Amgen Advances mCRC Care with LUMAKRAS-Vectibix Combo with FDA Approval.
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
This week, StockNews.AI identified and published 156 successful event alerts across multiple sectors. Notably, 10+% of these alerts highlighted price changes exceeding 10%, including one that doubled in value within a 24-hour timeframe. The majority of this week’s successful AI-driven events stemmed from Q4 financial report results.
*Data Captured Between 1/13 00:00am - 1/17 11:00 am EDT.
*Penny stocks are excluded from the 10%+ price change analysis.
Our Analytics Dashboard has been live for over a month, designed to save you time and elevate your financial strategies. If you haven’t explored it yet, now’s the perfect time to check it out!
Top 3 events you can’t miss for today, 1/17.
PRNewsWire
BullishLongTermPEPM&A
PEPSICO COMPLETES ACQUISITION OF SIETE FOODS
- PepsiCo acquired Siete Foods for $1.2 billion to expand its food portfolio.
- The acquisition focuses on positive nutrition and simple ingredients for consumers.
- Siete Foods has over 40,000 retail locations catering to health-conscious customers.
- PepsiCo's revenue reached over $91 billion in 2023, indicating strong market presence.
- Acquisition aligns with PepsiCo's sustainability vision for innovative and healthier products.
GlobeNewsWire
BullishLongTermBUSEM&A
First Busey Corporation Receives Federal Reserve Approval to Acquire CrossFirst Bankshares, Inc.
- Busey receives Federal Reserve approval for CrossFirst merger.
- Transaction enhances Busey's commercial banking and wealth management opportunities.
- Merger expected to close on March 1, 2025.
- Busey and CrossFirst integrate to improve financial performance.
- Busey recognized among the World's Best Banks for 2024.
PRNewsWire
BullishLongTermAMGNFDA Approval
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
- Amgen's LUMAKRAS and Vectibix combo approved by FDA for mCRC.
- Pivotal study showed over twofold progression-free survival improvement.
- LUMAKRAS targets KRAS G12C mutation in colorectal cancer treatment.
- Colorectal cancer accounts for 3rd most deaths in the US.
- New treatment may improve outcomes for mCRC patients significantly.
Here’re the top 5 most-surged stocks captured by our AI Event signal this week.
*Penny stocks are not included in the list.
Business Wire
BullishLongTerm 20.24%CURIEarnings
CuriosityStream Expands Content Licensing to Drive Revenue Growth and Meet Growing AI Training Demands
- CuriosityStream sees significant revenue growth from content licensing in 2024.
- AI-driven demand for video and image assets supports revenue expansion.
- Licensing revenue could surpass subscription revenue this year.
- CEO emphasizes CuriosityStream's unique position in AI content delivery.
- Company forecasts long-term revenue benefits from partnerships with tech firms.
GlobeNewsWire
VerybullishLongTerm 15.58%SYMM&A
Symbotic to Acquire Walmart's Advanced Systems and Robotics Business and Sign Related Commercial Agreement
- Walmart selects Symbotic to automate its APDs, enhancing eCommerce fulfillment.
- Agreement could add over $5 billion to Symbotic's future backlog.
- Walmart's store-fulfilled deliveries grew nearly 50% year-over-year.
- Transaction includes $520 million payment, with additional contingent consideration.
- Symbotic broadens its product offerings for efficient customer order fulfillment.
PRNewsWire
BullishShortTerm 13.18%CRGOEarnings
Freightos Reports Record Transactions and Carrier Additions for Fourth Quarter of 2024
- Freightos reported 350K transactions in Q4 2024, a 22% increase.
- Earnings exceeded management expectations, reflecting robust growth.
- Carrier network grew to 67, highlighting strong platform expansion.
- Gross Booking Value reached $280M, a 50% year-over-year increase.
- CEO emphasized digital transformation in the freight industry.
Business Wire
BearishShortTerm -11.89%PSNYEarnings
Polestar Publishes Selected Results for the Third Quarter and Updates FY 2024 Guidance
- Polestar revenue dropped 21% due to lower vehicle sales.
- Adjusted EBITDA improved by 11% despite increased operating losses.
- Cash balance decreased by 47%, raising liquidity concerns.
- Management changes aim to stabilize operations moving forward.
- 2024 guidance indicates further revenue decline and ongoing market pressures.
GlobeNewsWire
BullishLongTerm 10.71%NNEM&A
NANO Nuclear Energy Announces LOKI MMR as the New Tradename for its Newly Acquired Patented Pylon Transportable Reactor Platform
- NANO Nuclear rebranded its new Pylon reactor as LOKI MMR™.
- LOKI MMR™ supports 1.5MWe to 5MWe power for diverse applications.
- The reactor enhances NANO's space exploration energy solutions significantly.
- Initial LOKI MMR™ testing planned for 2026, now under review.
- Acquisition strengthens NANO's position in the modular nuclear reactor market.
PRNewsWire
VerybullishLongTerm 9.21%LTHEarnings
Life Time Reports Preliminary Estimated Fourth Quarter and Full-Year 2024 Financial Results and Introduces Select Fiscal 2025 Guidance
- Life Time expects Q4 2024 revenue to increase by 18.5%.
- Net income for Q4 2024 projected at 35% growth, reaching $31-$33 million.
- Guidance for FY 2025 revenue suggests a 12.2% increase to $2.91-$2.97 billion.
- Adjusted EBITDA forecasted to grow 14.1% in FY 2025, reflecting strong operations.
- Life Time anticipates improved member engagement and retention driving future growth.
By clicking on the ads, you’re directly supporting us to keep delivering quality content and insights, while also helping us earn revenue to continue our work. Every click makes a difference—thank you for your support!
Reasons you should be a Locked On NBA insider
What’s up, NBA fans! From our expert hosts who cover your team every day on our podcasts, we offer a free daily newsletter delivered right to your email so you don’t miss any of the action on the court. Get expert analysis, game previews, post-game breakdowns, trade talk, draft coverage, and more. We curate your daily ticket to everything NBA, giving you the rundown for each NBA team and the league news you need to know. Be one of thousands of fans who are already insiders - fast and easy.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Want something new? Choose one for the next newsletter topic✨ Poll closes on every Friday at 11:59pm! |
|
Login or Subscribe to participate in polls. |
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply